The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells

Predictive Value of PTEN and AR Coexpression of Sustained Responsiveness to Hormonal Therapy in Prostate Cancer—A Pilot Study

(2015) Soha Salama El Sheikh et al.   NEOPLASIA

Androgen receptor levels are upregulated by Akt in prostate cancer

(2011) S. Ha et al.   ENDOCRINE-RELATED CANCER

Targeting the Akt/mTOR pathway in Brca1-deficient cancers

(2011) T Xiang et al.   ONCOGENE

Docetaxel-based combination therapy for castration-resistant prostate cancer

(2010) M. D. Galsky et al.   ANNALS OF ONCOLOGY

Genipin Induced Apoptosis Associated with Activation of the c-Jun NH2-Terminal Kinase and p53 Protein in HeLa Cells

(2010) Houli Cao et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase

(2010) E Di Gennaro et al.   BRITISH JOURNAL OF CANCER

Reactive Oxygen Species-Dependent Apoptosis by Gugulipid Extract of Ayurvedic Medicine Plant Commiphora mukul in Human Prostate Cancer Cells Is Regulated by c-Jun N-Terminal Kinase

(2010) D. Xiao et al.   MOLECULAR PHARMACOLOGY

The Bioactive Compounds α-Chaconine and Gallic Acid in Potato Extracts Decrease Survival and Induce Apoptosis in LNCaP and PC3 Prostate Cancer Cells

(2010) Lavanya Reddivari et al.   NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL

Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer

(2010) Christoph W. M. Reuter et al.   WORLD JOURNAL OF UROLOGY

The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer

(2009) R Diaz et al.   BRITISH JOURNAL OF CANCER

Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer

(2008) Mari Nakabayashi et al.   BJU INTERNATIONAL

Cost-effectiveness of prostate cancer chemoprevention

(2008) Robert S. Svatek et al.   CANCER

Palomid 529, a Novel Small-Molecule Drug, Is a TORC1/TORC2 Inhibitor That Reduces Tumor Growth, Tumor Angiogenesis, and Vascular Permeability

(2008) Q. Xue et al.   CANCER RESEARCH

The current state of preclinical prostate cancer animal models

(2008) Kenneth J. Pienta et al.   PROSTATE

Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors

(2008) Claudio Festuccia et al.   PROSTATE

A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel

(2007) Robert W. Ross et al.   CANCER